Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5198031 | 0.88 | TGFBR1 (0.42) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5199379 | 0.87 | TGFBR1 (0.42) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5199950 | 0.85 | TGFBR1 (0.43) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5199747 | 0.85 | KDM4E (0.46) | TGFBR1MAPK14MTORRIPK2ACVR1B | |
| SCHEMBL5201015 | 0.85 | TGFBR1 (0.42) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5199896 | 0.85 | TGFBR1 (0.42) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5198178 | 0.85 | TGFBR1 (0.42) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5199327 | 0.84 | TGFBR1 (0.48) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5199569 | 0.84 | TGFBR1 (0.44) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5197647 | 0.84 | TGFBR1 (0.42) | TGFBR1MAPK14CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | TGFBR1 40/4885MAPK14 2998/4885CYP2D6 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.